Judith M. Versluis

2.0k total citations
43 papers, 408 citations indexed

About

Judith M. Versluis is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Judith M. Versluis has authored 43 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 20 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in Judith M. Versluis's work include Cancer Immunotherapy and Biomarkers (31 papers), CAR-T cell therapy research (18 papers) and Melanoma and MAPK Pathways (17 papers). Judith M. Versluis is often cited by papers focused on Cancer Immunotherapy and Biomarkers (31 papers), CAR-T cell therapy research (18 papers) and Melanoma and MAPK Pathways (17 papers). Judith M. Versluis collaborates with scholars based in Netherlands, Australia and United States. Judith M. Versluis's co-authors include Christian U. Blank, Georgina V. Long, Elisa A. Rozeman, Irene L. M. Reijers, Daniela S. Thommen, Alexander M. Menzies, Bart A. van de Wiel, Petros Dimitriadis, Karolina Sikorska and Andrew J. Spillane and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Judith M. Versluis

41 papers receiving 408 citations

Peers

Judith M. Versluis
E. Goode United Kingdom
Ming Gu China
Audrey Hennequin France
John M. Richart United States
Muhammad Zubair Afzal United States
Zhongmin Maxwell Wang Australia
Mahmood Al‐Dhaheri Qatar
Zhuxing Chen China
Francesca Bergomas Italy
E. Goode United Kingdom
Judith M. Versluis
Citations per year, relative to Judith M. Versluis Judith M. Versluis (= 1×) peers E. Goode

Countries citing papers authored by Judith M. Versluis

Since Specialization
Citations

This map shows the geographic impact of Judith M. Versluis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith M. Versluis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith M. Versluis more than expected).

Fields of papers citing papers by Judith M. Versluis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith M. Versluis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith M. Versluis. The network helps show where Judith M. Versluis may publish in the future.

Co-authorship network of co-authors of Judith M. Versluis

This figure shows the co-authorship network connecting the top 25 collaborators of Judith M. Versluis. A scholar is included among the top collaborators of Judith M. Versluis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith M. Versluis. Judith M. Versluis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Versluis, Judith M., et al.. (2024). Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma. Cancer Immunology Immunotherapy. 73(2). 28–28. 2 indexed citations
2.
Versluis, Judith M., Petros Dimitriadis, James S. Wilmott, et al.. (2024). Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma. Journal for ImmunoTherapy of Cancer. 12(4). e008125–e008125. 9 indexed citations
3.
Reijers, Irene L. M., Alexander M. Menzies, Judith M. Versluis, et al.. (2023). The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.. Journal of Clinical Oncology. 41(16_suppl). 101–101. 6 indexed citations
4.
5.
Schmitt, Christina, Esmée P. Hoefsmit, Thomas Fangmeier, et al.. (2023). Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections. Cancer Immunology Immunotherapy. 72(11). 3475–3489. 5 indexed citations
6.
Rozeman, Elisa A., Judith M. Versluis, Alexander M. Menzies, et al.. (2023). 1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma. Annals of Oncology. 34. S660–S661. 1 indexed citations
7.
Versluis, Judith M., et al.. (2023). Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nature Reviews Clinical Oncology. 20(6). 408–422. 22 indexed citations
8.
Hoefsmit, Esmée P., Elisa A. Rozeman, Irene L. M. Reijers, et al.. (2023). Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence. Cancer Research Communications. 3(4). 672–683. 9 indexed citations
9.
Serra-Bellver, Patricio, Judith M. Versluis, Cong Zhou, et al.. (2022). Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. European Journal of Cancer. 176. 121–132. 14 indexed citations
10.
Jacoberger-Foissac, Célia, Petros Dimitriadis, Marjolein de Bruijn, et al.. (2022). Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Science Translational Medicine. 14(642). eabj9779–eabj9779. 37 indexed citations
11.
Versluis, Judith M., Sofie Wilgenhof, A. Meerveld-Eggink, et al.. (2022). 854P Clinical features of acquired resistance (AR) in stage IV melanoma patients (pts) treated with immune checkpoint inhibition (ICI). Annals of Oncology. 33. S940–S940. 1 indexed citations
12.
Rozeman, Elisa A., Judith M. Versluis, Sofie Wilgenhof, et al.. (2022). Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Clinica Chimica Acta. 533. 71–78. 5 indexed citations
13.
Versluis, Judith M., Irene L. M. Reijers, Elisa A. Rozeman, et al.. (2021). Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. European Journal of Cancer. 148. 51–57. 14 indexed citations
14.
Bhave, Prachi, Tasnia Ahmed, Alexander N. Shoushtari, et al.. (2021). 1047P Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM). Annals of Oncology. 32. S876–S877. 3 indexed citations
15.
16.
Versluis, Judith M., Alison M. Weppler, Lauren Brown, et al.. (2020). 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition. Annals of Oncology. 31. S733–S734. 1 indexed citations
17.
Versluis, Judith M., Georgina V. Long, & Christian U. Blank. (2020). Learning from clinical trials of neoadjuvant checkpoint blockade. Nature Medicine. 26(4). 475–484. 135 indexed citations
18.
19.
Versluis, Judith M., Daniela S. Thommen, & Christian U. Blank. (2020). Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach. Journal for ImmunoTherapy of Cancer. 8(2). e001352–e001352. 14 indexed citations
20.
Versluis, Judith M., et al.. (2018). Leptomeningeal metastases of a well-differentiated neuroendocrine tumour: a rare entity. BMJ Case Reports. 2018. bcr–2018. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Goode Breakdown of academic impact, for papers by Ming Gu Breakdown of academic impact, for papers by Audrey Hennequin Breakdown of academic impact, for papers by John M. Richart Breakdown of academic impact, for papers by Muhammad Zubair Afzal Breakdown of academic impact, for papers by Zhongmin Maxwell Wang Breakdown of academic impact, for papers by Mahmood Al‐Dhaheri Breakdown of academic impact, for papers by Zhuxing Chen Breakdown of academic impact, for papers by Francesca Bergomas
Rankless by CCL
2026